Professor, Internal Medicine, UC, Davis School of Medicine
Hematology
Dr. Primo N. Lara Jr., MD
|
|
Give Review
Primo Lara practices Hematology. He studied medicine at University of the Philippines College of Medicine. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Primo Lara is a published doctor as well. He has 99 publications published. The latest was: New and emerging developments in extensive-stage small cell lung cancer therapeutics. He accepts Medicare.
Publications
- SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Perfo...
- New and emerging developments in extensive-stage small cell lung Cancer therapeutics.
- Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWO...
- Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced Malignant solid tumors.
- Implications of lymph node retrieval in locoregional rectal Cancer treated with chemoradiotherapy: A California Cancer Registry Study.
- Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate Cancer patients.
- Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncolog...
- Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung Cancer cell lines.
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase 3 metastatic castration resistant prostate Cancer trial.
- Papillary Renal Cell Carcinoma: Current Progress and Future Directions.
- Twenty years post-NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial acc...
- Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung Cancer.
- Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate Cancer cells and improves therapeutic response in a xenograft model.
- Left behind? Drug discovery in extensive-stage small-cell lung Cancer.
- Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Res...
- Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421.
- Dasatinib and docetaxel in advanced prostate Cancer.
- KRAS mutations in non-small-cell lung Cancer and colorectal Cancer: Implications for EGFR-targeted therapies.
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell Carcinoma.
- Acquired Resistance to Targeted Therapies Against Oncogene-Driven Non-Small-Cell Lung Cancer: Approach to Subtyping Progressive Disease and Clinical Implications.
- Evolving epidemiologic trends in nonclear cell renal cell Cancer: an analysis of the california Cancer registry.
- Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate Cancer (SWOG S0421): a randomised phase 3 trial.
- Chemotherapy Outcomes by Histologic Subtypes of Non-Small-Cell Lung Cancer: Analysis of the Southwest Oncology Group Database for Antimicrotubule-Platinum Therapy.
- Phase I study of the combination of temsirolimus and pazopanib in advanced solid Tumors.
- Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy.
- Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.
- Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder Cancer.
- Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity.
- Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry Analysis of 28,252 patients.
- Defining an individualized treatment strategy for metastatic renal Cancer.
- Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid Tumors.
- XL647-A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatm...
- Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial.
- Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003).
- Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non-Small-Cell...
- Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell Carcinoma: combined mTOR and AKT inhibitor therapy.
- A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell Carcinoma.
- Secondary malignancies among nonseminomatous germ cell tumor Cancer survivors.
- Biomarkers of DNA repair and related pathways: significance in non-small cell lung Cancer.
- Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung Cancer: a California Cancer consortium trial.
- Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung Cancer: final pati...
- Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung Cancer.
- Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder Cancer cells.
- Racial disparities on the use of invasive and noninvasive staging in patients with non-small cell lung Cancer.
- A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
- Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial Cancer, a California Cancer Consortium Trial.
- Identification of a bladder Cancer-specific ligand using a combinatorial chemistry approach.
- Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patie...
- EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung Cancer.
- Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell Cancer: SWOG S0317.
- Evolving treatment algorithms for advanced non-small-cell lung Cancer: 2009 looking toward 2012.
- Cooperative group research endeavors in small-cell lung Cancer: current and future directions.
- Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung Cancer: a model for assessing population-related pharmacogenomics.
- Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
- Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung Cancer: SWOG 0222.
- A sequential treatment approach to myoinvasive urothelial Cancer: a phase II Southwest Oncology Group trial (S0219).
- A Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer: Southwest Oncology Group Study S0312.
- Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung Cancer: clinical and pharmacogenomic results from SWOG S0124.
- Individualizing therapy for non-small-cell lung Cancer: a paradigm shift from empiric to integrated decision-making.
- The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung Cancer cells.
- Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung Cancer.
- Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung Cancer: exploring a new frontier.
- Predictors of survival of advanced renal cell Carcinoma: long-term results from Southwest Oncology Group Trial S8949.
- Oral fenretinide in biochemically recurrent prostate Cancer: a California Cancer consortium phase II trial.
- Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung Cancer patients receiving platinum-based chemotherapy: SWOG Study...
- Progress in small-cell lung Cancer: the lowest common denominator.
- Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate Cancer previously treated with taxanes.
- Positron emission tomography and improved survival in patients with lung Cancer: the Will Rogers phenomenon revisited.
- Monoclonal antibodies versus tyrosine kinase inhibitors concurrent with chemotherapy in non-small-cell lung Cancer: exploring divergent results.
- Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in Cancer.
- Aurora kinases as antiCancer drug targets.
- Overcoming barriers to Cancer clinical trial accrual: impact of a mass media campaign.
- Targeted therapies in non-small-cell lung Cancer: a paradigm in evolution.
- The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung Cancer: a California Cancer Consortium Phase I study.
- The AKT inhibitor perifosine in biochemically recurrent prostate Cancer: a phase II California/Pittsburgh Cancer consortium trial.
- Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung Cancer.
- Schedule-dependent apoptosis in K-ras mutant non-small-cell lung Cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
- Combination treatment of prostate Cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.
- Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease.
- Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung Cancer whose tumors have failed first-line platinum-based chemoth...
- Erlotinib and vinorelbine in advanced Malignant solid tumors: a phase I study.
- Incorporating bortezomib into the treatment of lung Cancer.
- Optimizing targeted therapy in patients with lung Cancer with a performance status of 2.
- Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung Cancer: biologic rationale for combination strategies.
- Biologic agents as adjunctive therapy for prostate Cancer: a rationale for use with androgen deprivation.
- Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatme...
- Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung Cancer: a Southwest Oncology Group phase II trial (S0327).
- Accrual issues in genitourinary Cancer clinical trials.
- Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung Cancer: a phase II Southwest Oncology G...
- Aurora kinase inhibitors: a new class of targeted drugs in Cancer.
- Second-line treatment for advanced-stage non-small-cell lung Cancer: current and future options.
- Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung Cancer.
- Evaluation of proState-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
- A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate Cancer patients with bone metastases.
- Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung Cancer.
- Bortezomib plus docetaxel in advanced non-small cell lung Cancer and other solid tumors: a phase I California Cancer Consortium trial.
- Molecular selection for therapy of patients with non-small-cell lung Cancer and impaired performance status: has the time come?
- Evaluation of factors affecting awareness of and willingness to participate in Cancer clinical trials.
Schools
University Of The Philippines Manila College Of Medicine
Rush Presby St Luke39s Mc
Uc Davis Cancer Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
University of California Davis -
Rush University Medical Center -
University of the Philippines College of Medicine
Hospital
-
University of California, Davis Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. David R. Gandara, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Tim W. Grennan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Tanaka Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vincent Caggiano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard M. Guy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karen L. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Derick H. Lau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah J. Perez, MD |
|
|
Dr. I-Ting Yu, MD |
|
|
Dr. Ted Wun, MD |
|
|
Dr. Kendra Hutchinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randeep S. Sangha, MD |